These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21491921)

  • 1. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.
    Riganti C; Voena C; Kopecka J; Corsetto PA; Montorfano G; Enrico E; Costamagna C; Rizzo AM; Ghigo D; Bosia A
    Mol Pharm; 2011 Jun; 8(3):683-700. PubMed ID: 21491921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells.
    Kopecka J; Campia I; Olivero P; Pescarmona G; Ghigo D; Bosia A; Riganti C
    J Control Release; 2011 Jan; 149(2):196-205. PubMed ID: 20946921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells.
    Doublier S; Riganti C; Voena C; Costamagna C; Aldieri E; Pescarmona G; Ghigo D; Bosia A
    Mol Cancer Res; 2008 Oct; 6(10):1607-20. PubMed ID: 18922976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
    Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
    Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with liposome-anchored pegylated peptides modulates doxorubicin sensitivity in P-glycoprotein-expressing P388 cells.
    Gatouillat G; Odot J; Balasse E; Nicolau C; Tosi PF; Hickman DT; López-Deber MP; Madoulet C
    Cancer Lett; 2007 Nov; 257(2):165-71. PubMed ID: 17517470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
    Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
    Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
    Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
    Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells.
    Shen X; Chen G; Zhu G; Fong WF
    Bioorg Med Chem; 2006 Nov; 14(21):7138-45. PubMed ID: 16875827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of multidrug resistance in cancer cells by Rhizoma Alismatis extract.
    Fong WF; Wang C; Zhu GY; Leung CH; Yang MS; Cheung HY
    Phytomedicine; 2007 Feb; 14(2-3):160-5. PubMed ID: 16713217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function.
    Elamanchili P; McEachern C; Burt H
    J Pharm Sci; 2009 Mar; 98(3):945-58. PubMed ID: 18623213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay.
    Susa M; Choy E; Yang C; Schwab J; Mankin H; Hornicek F; Duan Z
    J Biomol Screen; 2010 Mar; 15(3):287-96. PubMed ID: 20150589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes.
    Fong WF; Wan CK; Zhu GY; Chattopadhyay A; Dey S; Zhao Z; Shen XL
    Planta Med; 2007 Mar; 73(3):212-20. PubMed ID: 17318783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of apolipoprotein A1-modi liposome-doxorubicin with autophagy inhibitors overcame drug resistance in vitro.
    Wang B; Feng D; Han L; Fan J; Zhang X; Wang X; Ye L; Shi X; Feng M
    J Pharm Sci; 2014 Dec; 103(12):3994-4004. PubMed ID: 25354472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells.
    Kang DI; Kang HK; Gwak HS; Han HK; Lim SJ
    Drug Deliv; 2009 Jul; 16(5):261-7. PubMed ID: 19538007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cells.
    Riganti C; Campia I; Polimeni M; Pescarmona G; Ghigo D; Bosia A
    Toxicol Appl Pharmacol; 2009 Nov; 240(3):385-92. PubMed ID: 19647009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng.
    Choi CH; Kang G; Min YD
    Planta Med; 2003 Mar; 69(3):235-40. PubMed ID: 12677527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using L1210/VCR cells.
    Breier A; Drobná Z; Barancík M
    Neoplasma; 1998; 45(4):248-53. PubMed ID: 9890669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.